AGI AGI

TIDMAGI

RNS Number : 7506D

AGI Therapeutics plc

28 March 2011

AGI Therapeutics plc

('AGI' or the 'Company')

Directors' Dealing

AGI was informed on 25 March 2011 that David Kelly, a Director and Chief Financial Officer of AGI, purchased 550,000 ordinary shares of EUR0.01 each ("Ordinary Share") in the share capital of the Company at a price of EUR0.045 per Ordinary Share on 25 March 2011.

Following this purchase, David Kelly's beneficial shareholding in the Company is 655,000 Ordinary Shares.

Contact Information:

David G. Kelly, Chief Financial Officer Tel: +353 1 449 3254

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSPGUMPWUPGGWR

AGI (LSE:AGI)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025

AGI (LSE:AGI)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025